2019 – Amal Therapeutics

Geneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]

Amal Therapeutics to publish R&D outcomes in JCI Insight

24th April 2019/in News /by Jean-François Mayol

Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens), its […]

AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

24th April 2019/in News /by Aurelie Kowalski

Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF